S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Portage Biotech Stock Forecast, Price & News

+0.19 (+2.52%)
(As of 07/6/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
26,899 shs
Average Volume
57,623 shs
Market Capitalization
$103.06 million
P/E Ratio
Dividend Yield
Price Target

Portage Biotech MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
343.7% Upside
$34.25 Price Target
Short Interest
3.43% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($1.11) to ($1.28) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.72 out of 5 stars

Medical Sector

807th out of 1,433 stocks

Crude Petroleum & Natural Gas Industry

63rd out of 127 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

PRTG Stock News Headlines

Portage Biotech Inc. Common Stock (PRTG)
Portage Rings the Opening Bell
Portage Biotech Issues Letter to Shareholders
Portage Biotech Added to Russell 2000(R) Index
Portage Biotech Begins Public Offering of Shares
See More Headlines

Industry, Sector and Symbol

Crude petroleum & natural gas
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$12.22 per share


Free Float
Market Cap
$103.06 million
Not Optionable

Portage Biotech Frequently Asked Questions

Should I buy or sell Portage Biotech stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Portage Biotech stock.
View analyst ratings for Portage Biotech
or view top-rated stocks.

What is Portage Biotech's stock price forecast for 2022?

4 Wall Street research analysts have issued 12-month target prices for Portage Biotech's shares. Their PRTG stock forecasts range from $30.00 to $40.00. On average, they expect Portage Biotech's share price to reach $34.25 in the next twelve months. This suggests a possible upside of 343.7% from the stock's current price.
View analysts' price targets for Portage Biotech
or view top-rated stocks among Wall Street analysts.

How has Portage Biotech's stock price performed in 2022?

Portage Biotech's stock was trading at $10.73 at the beginning of the year. Since then, PRTG stock has decreased by 28.1% and is now trading at $7.72.
View the best growth stocks for 2022 here

When is Portage Biotech's next earnings date?

Portage Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 29th 2022.
View our earnings forecast for Portage Biotech

How were Portage Biotech's earnings last quarter?

Portage Biotech Inc. (NASDAQ:PRTG) posted its earnings results on Monday, November, 22nd. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03.
View Portage Biotech's earnings history

Who are Portage Biotech's key executives?

Portage Biotech's management team includes the following people:
  • Dr. Ian B. Walters M.B.A., M.D., CEO & Director (Age 54, Pay $568.5k)
  • Mr. Allan J. Lee Shaw CPA, Chief Financial Officer (Age 58, Pay $209.95k)
  • Mr. Steve Innaimo, VP of Project Management & Operations
  • Dr. Robert A. Kramer Ph.D., Chief Scientific Officer
  • Mr. Joseph Ciavarella, Chief Accounting Officer
  • Mr. Brian Wiley, Chief Bus. Officer (Age 54)

What is Portage Biotech's stock symbol?

Portage Biotech trades on the NASDAQ under the ticker symbol "PRTG."

How do I buy shares of Portage Biotech?

Shares of PRTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Portage Biotech's stock price today?

One share of PRTG stock can currently be purchased for approximately $7.72.

How much money does Portage Biotech make?

Portage Biotech (NASDAQ:PRTG) has a market capitalization of $103.06 million.

How can I contact Portage Biotech?

Portage Biotech's mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The official website for Portage Biotech is www.portagebiotech.com. The company can be reached via phone at 416-929-1806.

This page (NASDAQ:PRTG) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.